CTP 730

Drug Profile

CTP 730

Alternative Names: Apremilast deuterated; CTP-730; Deuterated apremilast

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Class Anti-inflammatories; Organic deuterium compounds; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (PO, Suspension)
  • 01 Jun 2015 Concert completes a phase I trial for Healthy volunteers in Australia (NCT02404922)
  • 01 May 2015 Concert Pharmaceuticals completes a phase I trial in Healthy volunteers in Australia (NCT02239081)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top